Canadian AIDS Treatment Information Exchange
click here to return to CATIE main menu
DonateNow

TESTING : High liver enzyme levels — a warning about survival?

TreatmentUpdate 129 - 2002 August ; Volume 14 Issue 6
Hosein SR
click here for french langage version of article

Lab tests can detect levels of certain proteins commonly called "liver enzymes." Two examples of these enzymes include:

ALT is made by the liver. AST is made mostly by the liver but also by several other organs/systems, in decreasing order: the heart, skeletal muscles, kidneys, brain, pancreas, lungs, white and red blood cells. Yet, AST is still commonly considered a liver enzyme.

In general, liver enzyme levels rise above normal when the liver is being damaged. In some people with HIV/AIDS (PHAs), higher-than-normal levels of liver enzymes are common, perhaps caused by hepatitis, the toxicity of anti-HIV medications and the use of alcohol and other drugs.

Study details

Researchers at the University of Pittsburg analysed information from a large database on nearly 7,000 subjects to find a link between higher-than-normal liver enzymes, a condition called transaminitis, and survival. They considered liver enzymes to be high when they were at levels twice above normal.

Results

The researchers found that higher-than-normal levels, particularly of AST, were associated with reduced chances of survival. These high AST levels were linked to the following:

Even after researchers adjusted their calculations by taking into account subjects who had low CD4+ cell counts and high viral loads (and who were therefore at increased risk of death), having elevated AST levels was linked to reduced survival when compared to PHAs who had normal AST levels.

The researchers concluded that high liver enzyme levels have a major connection to survival. They suggest that even mildly elevated levels of liver enzymes deserve attention.

REFERENCE

Justice AC, Wagner JH, Fusco GP, et al. HIV survival: liver function tests independently predict survival. XIV International AIDS Conference, July 7-12, 2002, Barcelona. Abstract MoOrB1058.

20020810
CATE12907


Copyright © 2002 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284  http://www.catie.ca.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.